We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Brain Cancer

Journal Scan / Research · May 07, 2020

Continuing Adjuvant Temozolomide Beyond Six Cycles in GBM Does Not Improve PFS



Additional Info

Disclosure statements are available on the authors' profiles:

A Phase II Randomized, Multicenter, Open-Label Trial of Continuing Adjuvant Temozolomide Beyond Six Cycles in Patients With Glioblastoma (GEINO 14-01)
Neuro-oncology 2020 Apr 24;[EPub Ahead of Print], C Balana, MA Vaz, JM Sepúlveda, C Mesia, S Del Barco, E Pineda, J Muñoz-Langa, A Estival, R de Las Peñas, J Fuster, R Gironés, LM Navarro, M Gil-Gil, M Alonso, A Herrero, S Peralta, C Olier, P Perez-Segura, M Covela, M Martinez-García, A Berrocal, O Gallego, R Luque, FJ Perez-Martín, A Esteve, N Munne, M Domenech, S Villa, C Sanz, C Carrato

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading